Skip to Main content Skip to Navigation
Master Thesis

Efficacité et sécurité du cyclophosphamide dans la sarcoïdose : une cohorte rétrospective

Abstract : Introduction: cyclophosphamide is used in the management of severe refractory sarcoidosis. Current recommendations cannot position its use, for lack of available data. Methods: we performed a retrospective single-center cohort of patients with sarcoidosis according to WASOG criteria, treated with cyclophosphamide between 2008 and 2020. We evaluated response to treatment according to criteria of overall response, relapse rate and use of COS and ePOST scores. A cohort of organ damage was constituted to define efficacy according to each form. Results: on the 28 patients included in the cohort, cyclophosphamide led to remission in 22 patients, i.e., an efficacy of 78.6%. At six months after the end of treatment, the relapse rate was 44.4 %. This rate was then stable throughout the follow-up, at 51.8% at the end of the study after an average follow-up time of 29.21 months. Efficacy was greater than 90% in the pulmonary, cardiovascular, osteoarticular and neurological forms. However, the relapse rate in the neurological forms was high at 48% during follow-up. The predictive factors for relapse were a high adjusted ePOST score before treatment and an associated corticosteroid therapy < 0.5 mg/kg/d. 39% of the patients presented a serious adverse event and 28.5% an infectious complication during the follow-up. Conclusion: cyclophosphamide was effective in the treatment of refractory, systemic sarcoidosis, particularly in severe neurological, cardiac, or pulmonary forms.
Complete list of metadata
Contributor : Médecine Ub Connect in order to contact the contributor
Submitted on : Tuesday, November 2, 2021 - 2:12:48 PM
Last modification on : Wednesday, December 8, 2021 - 3:55:31 AM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2023-09-26

Please log in to resquest access to the document


  • HAL Id : dumas-03411644, version 1



Thomas Pires. Efficacité et sécurité du cyclophosphamide dans la sarcoïdose : une cohorte rétrospective. Sciences du Vivant [q-bio]. 2021. ⟨dumas-03411644⟩



Les métriques sont temporairement indisponibles